Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261798 | 1.00 | KMO (0.45) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL25485771 | 0.86 | KMO (0.43) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL5528099 | 0.81 | KMO (0.45) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL21200420 | 0.81 | ALOX15 (0.41) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL25136303 | 0.80 | KMO (0.44) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL16095194 | 0.80 | MAPT (0.46) | LMNARBP4MRGPRX4HPGDMAPT | |
| SCHEMBL7878295 | 0.80 | LMNA (0.62) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL6468496 | 0.77 | NT5E (0.42) | ALOX15TSHRNT5EHPGDKMT2A | |
| SCHEMBL25136323 | 0.76 | CYP1A2 (0.45) | MEN1POLBHPGDRAB9AKMT2A | |
| SCHEMBL12097960 | 0.76 | CES2 (0.45) | KMOALOX15TSHRHIF1ARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514858-B2 | CD38 inhibitors | Astellas Engineered Small Molecules US, Incorporated (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250326739-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4587427-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | BenevolentAI Cambridge Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4532483-A1 | CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024057001-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | Benevolentai Cambridge Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| EP-4132919-A1 | CD38 INHIBITORS | Mitobridge, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115697985-A | CD38 inhibitors | 米托布里奇公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | KMO 4227/4885LMNA 3192/4885ALOX15 4386/4885 |
| US-20250326739-A1 | CD38 MODULATORS AND USES THEREOF | CD38, CD22, CD47 | KMO 4644/4885LMNA 1581/4885ALOX15 1360/4885 |
| US-20230158024-A1 | CD38 INHIBITORS | CD38, NQO1, NDUFAB1 | KMO 2001/4885LMNA 1093/4885ALOX15 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.